Morgan Stanley maintains Aptiv at Equal-Weight, lowers price target to $45 from $55

What happened

Morgan Stanley kept its Equal-Weight rating on Aptiv but cut its price target to $45 from $55, an 18.2% decrease. The new target implies 8.9% upside from Aptiv’s Nov. 3 closing price of $41.34.

Confirmed

Global impact / market context

The lower target signals Morgan Stanley sees less potential share-price upside than before, while its unchanged Equal-Weight rating indicates it did not change its overall stance. If investors respond by reassessing expectations, Aptiv’s share price and the cost of raising capital could be affected.

Analyst inference

Other recent analyst targets listed in the article range from $53 to $64, above Morgan Stanley’s new $45 target. That gap shows differing analyst expectations, but the article gives no company operating results or explanation for Morgan Stanley’s reduction.

Confirmed

What to watch

1. Compare future analyst target changes with Aptiv’s reported business results; the article provides no reason for Morgan Stanley’s cut, so its implications for revenue or costs remain unclear. Analyst inference
2. Check whether Morgan Stanley changes its Equal-Weight rating or adjusts the $45 target again, which would show whether its view of Aptiv has shifted further. Analyst inference
3. The article reports a $41.34 Nov. 3 close and says the $45 target implies 8.9% upside; it reports no subsequent share-price movement. Confirmed

Evidence

• Original source link unavailable